Erratum: Worldwide Argus II implantation: Recommendations to optimize patient outcomes (BMC Ophthalmology (2016) 16 (52) DOI: 10.1186/s12886-016-0225-1);Worldwide Argus II implantation: Recommendations to optimize patient outcomes

BMC Ophthalmology

Volumn 16, Issue 1, 2016, Pages

  Ghodasra, Devon H ^a   Chen, Adrienne ^a   Arevalo, J Fernando ^b   Birch, David G ^c   Branham, Kari ^a   Coley, Brian ^d   Dagnelie, Gislin ^b   De Juan, Eugene ^e   Devenyi, Robert G ^f   Dorn, Jessy D ^d   Fisher, Andy ^g   Geruschat, Duane R ^b   Gregori, Ninel Z ^h   Greenberg, Robert J ^d   Hahn, Paul ⁱ   Ho, Allen C ^j   Howson, Ashley ^a   Huang, Suber S ^k   Iezzi, Raymond ^l   Khan, Naheed ^a   Lam, Byron L ^h   Lim, Jennifer I ^m   Locke, Kirsten G ^c   Markowitz, Michelle ⁿ   Ripley, Anne Marie ^d   Rankin, Mark ^o   Schimitzek, Hannah ^p   Tripp, Fay ⁱ   Weiland, James D ^q   Yan, Jiong ^r   Zacks, David N ^a   Jayasundera, K Thiran ^a   more..

^a UNIVERSITY OF MICHIGAN   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c RETINA FOUNDATION OF THE SOUTHWEST   (United States)

^d Second Sight Medical Products Inc   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g Focal Point   (United Kingdom)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ DUKE UNIVERSITY EYE CENTER   (United States)

^j WILLS EYE HOSPITAL   (United States)

^k Retina Center of Ohio   (United States)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁿ Private Practice   (Canada)

^o Canadian National Institute for the Blind   (Canada)

^p RWTH AACHEN UNIVERSITY   (Germany)

^q UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^r EMORY EYE CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLINDNESS; ELECTRODE IMPLANT; HUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PROCEDURES; PROSTHESIS IMPLANTATION; RETINITIS PIGMENTOSA; VISUAL PROSTHESIS;

BLINDNESS; ELECTRODES, IMPLANTED; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PROSTHESIS IMPLANTATION; RETINITIS PIGMENTOSA; VISUAL PROSTHESIS;

EID: 84969567834     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/s12886-016-0259-4     Document Type: Erratum

References (24)

1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795-809.
2. Daiger SP, Sullivan LS, Bowne SJ. RetNet: Retinal Information Network. 2015. https://sph.uth.edu/retnet/. Accessed 26 Jul 2015.
3. Food and Drug Administration. FDA approves first retinal implant for adults with rare genetic eye disease. FDA News Release. 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm339824.htm. Accessed 26 Jul 2015.
4. da Cruz L, Coley BF, Dorn J, et al. The Argus II epiretinal prosthesis system allows letter and word reading and long-term function in patients with profound vision loss. Br J Ophthalmol. 2013;97(5):632-6.
5. Kotecha A, Zhong J, Stewart D, da Cruz L. The Argus II prosthesis facilitates reaching and grasping tasks: a case series. BMC Ophthalmol. 2014;14(71):1-8.
6. Barry MP, Dagnelie G. Use of the Argus II retinal prosthesis to improve visual guidance of fine hand movements. Investig Ophthalmol Vis Sci. 2012;53(9):5095-101.
7. Humayun MS, Dorn JD, Da Cruz L, et al. Interim results from the international trial of second sight's visual prosthesis. Ophthalmology. 2012;119(4):779-88.
8. Ahuja AK, Dorn JD, Caspi A, et al. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol. 2011;95(4):539-43.
9. Greenberg RJ, Humayun MS, da Cruz L, et al. Five-year data from the Argus II Retinal Prosthesis System. ARVO 2015 E-abstract 754.
10. Vaidya A, Borgonovi E, Taylor RS, et al. The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients. BMC Ophthalmol. 2014;14:49.
11. Black J, Hickson L, Black B. Defining and evaluating success in paediatric cochlear implantation - An exploratory study. Int J Pediatr Otorhinolaryngol. 2012;76(9):1317-26.
12. Soman UG, Kan D, Tharpe AM. Rehabilitation and educational considerations for children with cochlear implants. Otolaryngol Clin North Am. 2012;45(1):141-53.
13. U.S. National Institutes of Health. ClinicalTrials.gov: Argus II Retinal Prosthesis System Dry AMD Feasibility Study Protocol. 2015. https://clinicaltrials.gov/ct2/show/NCT02227498. Accessed 3 Nov 2015.
14. Ahuja a K, Yeoh J, Dorn JD, et al. Factors Affecting Perceptual Threshold in Argus II Retinal Prosthesis Subjects. Transl Vis Sci Technol. 2013;2(4):1.
15. Jensen RJ, Rizzo JF, Ziv OR, Grumet A, Wyatt J. Thresholds for activation of rabbit retinal ganglion cells with an ultrafine, extracellular microelectrode. Investig Ophthalmol Vis Sci. 2003;44(8):3533-43.
16. Ziv OR, Rizzo JF, Jensen RJ. In vitro activation of retinal cells: estimating location of stimulated cell by using a mathematical model. J Neural Eng. 2005;2(1):S5-S15.
17. Ho AC, Humayun MS, Dorn JD, et al. Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind. Ophthalmology. 2015;122(8):1547-54. doi: 10.1016/j.ophtha.2015.04.032.
18. Aleman TS, Cideciyan AV, Sumaroka A, et al. Inner retinal abnormalities in X-linked retinitis pigmentosa with RPGR mutations. Investig Ophthalmol Vis Sci. 2007;48(10):4759-65.
19. Rizzo S, Belting C, Cinelli L, et al. The Argus II retinal prosthesis: 12-month outcomes from a single-study center. Am J Ophthalmol. 2014;157(6):1282-90.
20. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Three-Year Follow-up of the Tube Versus Trabeculectomy Study. Am J Ophthalmol. 2009;148(5):670-84.
21. Humayun MS, Dorn JD, Ahuja AK, et al. Preliminary 6month results from the Argus II epiretinal prosthesis feasibility study. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:4566-8.
22. Geruschat DR, Flax M, Tanna N, et al. FLORA™: Phase I development of a functional vision assessment for prosthetic vision users. Clin Exp Optom. 2015;98(4):342-7.
23. Dagnelie G, Jeter PE, Adeyemo K, Rozanski C, Nkodo A-F, Massof RW. Psychometric properties of the PLoVR ultra-low vision (ULV) questionnaire. IOVS. 2014;55:E - Abstract 2150.
24. Dagnelie G, Barry MP, Adeyemo O, Jeter PE, Massof RW. Twenty Questions: An adaptive version of the PLoVR ultra-low vision (ULV) questionnaire. IOVS. 2015;56:E - Abstract 497.